Abstract

*Yash B. Gagare, Sager S. Gawade, Pradip R. Mandhare, Yuvraj B. Guldagad and Manoj L. Chaudhari

ABSTRACT

Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is an oral anti-diabetic agent used to treat type 2 diabetes mellitus. This study aimed to estimate Linagliptin in pharmaceutical formulations using a validated RP-HPLC method and review its anti-diabetic activity. The RP-HPLC method was developed and validated as per ICH guidelines, using a C18 column and a mobile phase consisting of phosphate buffer and acetonitrile. The method showed good linearity, accuracy, and precision. Linagliptin inhibits DPP-4 enzyme, thereby increasing the levels of incretin hormones, which stimulate insulin release and decrease glucagon levels. This results in improved glycemic control in type 2 diabetic patients. The validated RP-HPLC method can be used for routine analysis of Linagliptin in pharmaceutical formulations. The anti-diabetic activity of Linagliptin makes it a valuable therapeutic option for the management of type 2 diabetes mellitus.